LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 619soft tissue
alveolar, 369
chemotherapy for, 368
clinical presentation, 365, 370
clinical presentation of
nonmetastatic, 367, 372
prognosis, 369
recurrent, 367, 372
staging of, 366, 370
treatment, 365, 366, 367, 368,
370, 371
Sarcomatoid mesothelioma, 485
SCCHN.SeeSquamous cell cancer
of the head and neck
(SCCHN)
SCLC.SeeSmall cell lung cancer
(SCLC)
Scleroderma, 223
SCTAT.SeeSex cords tumors with
annular tubules (SCTAT)
Secondary prevention, 141, 142,
145
Second cancers
genetic susceptibility and, 60,
65–66
induction of, 60, 65
Second messengers, 7, 16
SEER.SeeSurveillance,
Epidemiology, and End
Results (SEER)
SEER database, 473
Seminoma
categories of, 302–303
CD117 and, 297, 301
orchiectomy and, 298, 302
PLAP and, 297, 301
radiation therapy in, 298,
301–302
relapse rate of, 298, 302
Senescence, 2, 5, 6, 9, 13, 14
replicative, 18, 26
Sentinel node biopsy (SNB), 335
lymphedema and, 344
Sentinel node mapping, 379
Serum free light chain (SFLC), 466
Serum galactomannan assay, 547
Serum protein electrophoresis
(SPEP), 463
Serum PSA, in prostate cancer
screening, 181
Sex cords tumors with annular
tubules (SCTAT), 160
Sezary syndrome (SS), 420, 432 ́
SFLC.SeeSerum free light chain
(SFLC)
SGN-35 antibody, 427, 435
Shark cartilage supplements, 593,
596
Siewert classification, 235, 241Single nucleotide polymorphisms
(SNP), 71, 75
ABO blood group, 73, 76
CHRNA3 and CHRNA5 genes
in, 72, 76
Sipuleucel-T, 109, 113
Sjogren’s syndrome, 223
Skin cancer
development of, 60, 66
family history of, 60, 66
skin pigment and, 60, 66
UV light exposure and, 57, 63
SLL.SeeSmall lymphocytic
lymphoma (SLL)
Small bowel adenocarcinoma, 263,
267
Small bowel malignancy, 263, 267
Small cell carcinoma and cigarette
smoking, 43
Small cell lung cancer (SCLC), 206,
211, 503, 506, 517, 522
carboplatin and, 209, 213
chemotherapy for, 506
cisplatin and, 207, 211
C-myc amplification in, 4, 11
and Cushing’s syndrome, 517,
522
and ectopic ACTH production,
517, 518, 522
etoposide chemotherapy and,
207, 211
PCI and, 206, 211
tumors location in, 506
Small intestinal cancer
celiac disease and, 263, 267
Crohn’s disease and, 263, 267
familial adenomatous polyposis
and, 263, 267
hereditary nonpolyposis
colorectal cancer and, 263,
267
Small lymphocytic lymphoma
(SLL), 414
Small round blue cell tumors, of
childhood, 400, 409
Smokeless tobacco
esophageal cancer and, 34, 44
and oral cavity cancer, 34, 44
pancreatic cancer and, 34, 44
Smoking cessation and NRT, 135,
138
SMZL.SeeSplenic marginal zone
lymphoma (SMZL)
SNB.SeeSentinel node biopsy
(SNB)
SNP.SeeSingle nucleotide
polymorphisms (SNP)
Societal issues, in oncology,
581–588Solid ankle-foot orthosis, 574,
578
Sonography, for chest lesion, 165
Sorafenib, 19, 27
in metastatic renal cell carcinoma
treatment, 80, 83
Southwest Oncology Group
(SWOG), 213
Soy products consumption and
breast cancer, 62, 68
Soy supplements, 590, 594
Spectroscopy, 177
Speech therapists, 577
SPEP.SeeSerum protein
electrophoresis (SPEP)
Spinal cord injury (SCI), in cancer
patients, 574, 578
Spinal ependymoma, NF2
mutations and, 384, 389
Spine fracture, treatment modalities
for, 574, 578
Spironolactone, 491
therapy, 495
Splenic marginal zone lymphoma
(SMZL), 416, 430
Splenic rupture, and anemia, 551,
556
Sporadic medullary thyroid
carcinoma, 137, 140
SPRED1gene, 35, 46
Squamous cell cancer of the head
and neck (SCCHN), 195, 199
alcohol use and, 195, 199
cetuximab, 197, 201
chemoradiation for, 197,
200–201
cisplatin, 196, 200
epidermal growth factor receptor,
195, 199
Fanconi’s anemia and, 195, 199
5-FU, 196, 200
HPV and, 195, 199
induction chemotherapy, 198, 203
management of, 200
risk factors for, 195, 199
second primaries in patients with,
198, 202
tobacco use and, 195, 199
Squamous cell carcinoma
and cigarette smoking, 43
hypercalcemia and, 519, 523
and Plummer-Vinson syndrome,
145
Src, 9
SS.SeeS ́ezary syndrome (SS)
Stem cell transplantation, 525–537
St. John’s Wort, 589, 594
Stochastic model, of tumor
heterogeneity, 23, 32